Tech Company Inital Public Offerings
Intellia Therapeutics IPO
Intellia Therapeutics, operating out of Cambridge, debuted as a public company on 5/6/2016.
Transaction Overview
Company Name
Announced On
5/6/2016
Transaction Type
IPO
Amount
$108,000,000
Proceeds Purpose
We currently intend to use the net proceeds from this offering as follows: $25.0 million to advance the research and development of our product candidates for our sentinel indications through to the submission of at least one IND; $15.0 million to progress additional in vivo and ex vivo pipeline product candidates; $10.0 million to further develop our delivery technologies and CRISPR/Cas9 gene editing platform; and the remainder for working capital and other general corporate purposes.
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
40 Erie St.
Cambridge, MA 02139
USA
Cambridge, MA 02139
USA
Phone
Website
Email Address
Not Recorded
Overview
Intellia (NASDAQ: NTLA) is a leading gene editing company, focused on the development of proprietary, potentially curative therapeutics using a recently developed biological tool known as the CRISPR/Cas9 system.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
John Leonard
Chief Financial Officer
Glenn Goddard
Vice President
Eliana Clark
VP - Bus. Development
Christine Foster
VP - General Counsel
Nishla Keiser
VP - General Counsel
Jose Rivera
Browse more venture capital transactions:
Prev: 5/6/2016: Envoy Commerce venture capital transaction
Next: 5/6/2016: MindShare Medical venture capital transaction
Share this article
Where The Data Comes From
We do our best to record every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs